BioCentury | May 23, 2013
Cover Story

IRS audit for tumors

...growth factor-1 receptor , a cancer-associated receptor tyrosine kinase . The new compounds, licensed to NovoTyr Therapeutics Ltd....
...Inc. 's linsitinib ( ASP7487 ), which is in Phase III trials for adrenocortical carcinoma. NovoTyr...
...that have been licensed to NovoTyr. Mixed signals Levitzki and Hadas Reuveni, study coauthor and NovoTyr's...
BioCentury | May 23, 2013
Distillery Therapeutics

Indication: Cancer

...6(20); doi:10.1038/scibx.2013.493 Published online May 23, 2013 Patent pending; available for licensing or partnering from NovoTyr Therapeutics Ltd....
Items per page:
1 - 2 of 2
BioCentury | May 23, 2013
Cover Story

IRS audit for tumors

...growth factor-1 receptor , a cancer-associated receptor tyrosine kinase . The new compounds, licensed to NovoTyr Therapeutics Ltd....
...Inc. 's linsitinib ( ASP7487 ), which is in Phase III trials for adrenocortical carcinoma. NovoTyr...
...that have been licensed to NovoTyr. Mixed signals Levitzki and Hadas Reuveni, study coauthor and NovoTyr's...
BioCentury | May 23, 2013
Distillery Therapeutics

Indication: Cancer

...6(20); doi:10.1038/scibx.2013.493 Published online May 23, 2013 Patent pending; available for licensing or partnering from NovoTyr Therapeutics Ltd....
Items per page:
1 - 2 of 2